Cited by 865Bone health and treatmentsBone health and osteoporosis researchBone Metabolism and Diseases

The DOI matches its Crossref record; 71 of the 75 references it cites were found in a registry or an index.

Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite

Nancollas, G.H., Tang, R., Phipps, R.J., Henneman, Z., Gulde, S., Wu, W., Mangood, A., Russell, R.G.G., Ebetino, F.H.·2006·Bone

DOI 10.1016/j.bone.2005.05.003

Open this paper in CoChat — free account

Abstract

Bisphosphonates are now the most widely used drugs for diseases associated with increased bone resorption, such as osteoporosis. Although bisphosphonates act directly on osteoclasts, and interfere with specific biochemical processes such as protein prenylation, their ability to adsorb to bone mineral also contributes to their potency and duration of action. The aim of the present study was to compare the binding affinities for hydroxyapatite (HAP) of 6 bisphosphonates currently used clinically and to determine the effects of these bisphosphonates on other mineral surface properties including zeta potential and interfacial tension. Affinity constants (K(L)) for the adsorption of bisphosphonates were calculated from kinetic studies on HAP crystal growth using a constant composition method at 37 degrees C and at physiological ionic strength (0.15 M). Under conditions likely to simulate bisphosphonate binding onto bone, there were significant differences in K(L) among the bisphosphonates for HAP growth (pH 7.4) with a rank order of zoledronate > alendronate > ibandronate > risedronate > etidronate > clodronate. The measurements of zeta potential show that the crystal surface is modified by the adsorption of bisphosphonates in a manner best explained by molecular charges related to the protonation of their side-chain moieties, with risedronate showing substantial differences from alendronate, ibandronate, and zoledronate. The studies of the solid/liquid interfacial properties show additional differences among the bisphosphonates that may influence their mechanisms for binding and inhibiting crystal growth and dissolution. The observed differences in kinetic binding affinities, HAP zeta potentials, and interfacial tension are likely to contribute to the biological properties of the various bisphosphonates. In particular, these binding properties may contribute to differences in uptake and persistence in bone and the reversibility of effects. These properties, therefore, have potential clinical implications that may be important in understanding differences among potent bisphosphonates, such as the apparently more prolonged duration of action of alendronate and zoledronate compared with the more readily reversible effects of etidronate and risedronate.

Integrity signals

Registry

Crossref · 10.1016/j.bone.2005.05.003

Cites

71 of 71 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The Dynamics of Capillary Flow
Washburn, E. W. (1921) · Physical Review · doi:10.1103/physrev.17.273 · Cited by 7,202
Zeta Potential in Colloid Science
(1981) · Elsevier eBooks · doi:10.1016/c2013-0-07389-6 · Cited by 2,349
Interfacial Forces in Aqueous Media
van Oss, C. J. (2006) · CRC Press eBooks · doi:10.1201/9781420015768 · Cited by 1,921
Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal Women
Bone, H. G., Hosking, D., Devogelaer, J.-P., Tucci, J. R., Emkey, R. D., Tonino, R. P., Rodriguez-Portales, J. A., Downs, R. W., Gupta, J., Santora, A. C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030897 · Cited by 1,347
The Effects of Parathyroid Hormone and Alendronate Alone or in Combination in Postmenopausal Osteoporosis
Black, D. M., Greenspan, S. L., Ensrud, K. E., Palermo, L., McGowan, J., Lang, T., Garnero, P., Bouxsein, M., Bilezikian, J. P., & Rosen, C. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa031975 · Cited by 1,168
Structure-Activity Relationships for Inhibition of Farnesyl Diphosphate Synthase in Vitro and Inhibition of Bone Resorption in Vivo by Nitrogen-Containing Bisphosphonates
Dunford, J. E., Thompson, K., Coxon, F. P., Luckman, S. P., Hahn, F. M., Poulter, C. D., Ebetino, F. H., & Rogers, M. J. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38786-5 · Cited by 900
Self-citation
Interfacial Forces in Aqueous Media
Visser, H. (1995) · Powder Technology · doi:10.1016/0032-5910(95)90005-5 · Cited by 884
Kinetics of Precipitation.
Liotta, S. (1965) · Journal of the American Chemical Society · doi:10.1021/ja01084a069 · Cited by 881
Intravenous Zoledronic Acid in Postmenopausal Women with Low Bone Mineral Density
Reid, I. R., Brown, J. P., Burckhardt, P., Horowitz, Z. D., Richardson, P. A., Trechsel, U., Widmer, A., Devogelaer, J.-P., Kaufman, J., Jaeger, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011807 · Cited by 870
Bisphosphonates: from the laboratory to the clinic and back again
Russell, R. G. G., & Rogers, M. J. (1999) · Bone · doi:10.1016/s8756-3282(99)00116-7 · Cited by 838
Self-citation

Flagged first, then by citations

Show all 75 references

4 of the 75 references couldn’t be matched to a known paper.

Research works printed but not linked: 9

Benedict J.J., The physical chemistry of the diphosphonates—Its relationship to their medical activity. In: Donath A., Courvoisier B., editors. Symposium Cemo, Centre D'Etude des Maladies Osteoarticulatires de Geneve (IV), 1–19. 1982. Geneva, Editions Medicine et Hygiene. Diphosphonates and Bone;1990:7–9.
Sunberg, 1991, Designing drugs for stronger bones, Chemtech, 21, 304
Ebetino, 1998, Mechanisms of action of etidronate and other bisphosphonates, Rev. Contemp. Pharmacother., 9, 233
Traube, 1927, Solubility and surface tension, Ber, 60B, 1808
Semenchenko, 1934, Solubility and surface tension, Uspekhi Khimii, 3, 710
Bagda, 1978, The relation between surface tension and the solubility parameter in liquids, Farbe Lack, 84, 212
Leu, 2004, Relative binding affinities of bisphosphonates for human bone, Bone, 34, S62
Christiansen, 2003, Comparison of risedronate and alendronate pharmacokinetics at clinical doses, Osteoporos Int., 14, S38
Watts, 2004, Treatment discontinuation effects on bone turnover and BMD with risedronate, Bone, 34, S99

Sorted by citations

Atypical subtrochanteric and diaphyseal femoral fractures: Second report of a task force of the American Society for Bone and Mineral Research
Shane, E., Burr, D., Abrahamsen, B., Adler, R. A., Brown, T. D., Cheung, A. M., Cosman, F., Curtis, J. R., Dell, R., Dempster, D. W., et al. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1998 · Cited by 2,147
Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy
Russell, R. G. G., Watts, N. B., Ebetino, F. H., & Rogers, M. J. (2008) · Osteoporosis International · doi:10.1007/s00198-007-0540-8 · Cited by 1,442
Self-citation
Osteoporosis
Sambrook, P. N., & Cooper, C. C. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68891-0 · Cited by 1,201
Bisphosphonates: The first 40years
Russell, R. G. G. (2011) · Bone · doi:10.1016/j.bone.2011.04.022 · Cited by 1,164
Self-citation
Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research
Shane, E., Burr, D., Ebeling, P. R., Abrahamsen, B., Adler, R. A., Brown, T. D., Cheung, A. M., Cosman, F., Curtis, J. R., Dell, R., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.253 · Cited by 1,116
Calcium Orthophosphates: Crystallization and Dissolution
Wang, L., & Nancollas, G. H. (2008) · Chemical Reviews · doi:10.1021/cr0782574 · Cited by 1,064
Self-citation
Denosumab and bisphosphonates: Different mechanisms of action and effects
Baron, R., Ferrari, S., & Russell, R. G. G. (2010) · Bone · doi:10.1016/j.bone.2010.11.020 · Cited by 738
Self-citation
Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research
Adler, R. A., Fuleihan, G. E., Bauer, D. C., Camacho, P. M., Clarke, B. L., Clines, G. A., Compston, J. E., Drake, M. T., Edwards, B. J.-A., Favus, M. J., et al. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2708 · Cited by 689
Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass
Bone, H. G., Bolognese, M. A., Yuen, C. K., Kendler, D. L., Miller, P. D., Yang, Y., Grazette, L. P., Martín, J. S., & Gallagher, J. C. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1502 · Cited by 634
Nanoparticle decoration with surfactants: Molecular interactions, assembly, and applications
Heinz, H., Pramanik, C., Heinz, Ö., Ding, Y., Mishra, R. K., Marchon, D., Flatt, R. J., Estrela‐Lopis, I., Llop, J., Moya, S. E., et al. (2017) · Surface Science Reports · doi:10.1016/j.surfrep.2017.02.001 · Cited by 629
Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial
Leder, B. Z., Tsai, J. N., Uihlein, A. V., Wallace, P. M., Lee, H., Neer, R. M., & Burnett‐Bowie, S. M. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61120-5 · Cited by 618
Molecular Mechanisms of Action of Bisphosphonates: Current Status
Roelofs, A. J., Thompson, K., Gordon, S., & Rogers, M. J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0843 · Cited by 572
Bone tissue engineering therapeutics: controlled drug delivery in three-dimensional scaffolds
Mouriño, V., & Boccaccini, A. R. (2009) · Journal of The Royal Society Interface · doi:10.1098/rsif.2009.0379 · Cited by 528
Bisphosphonates: Mode of Action and Pharmacology
Russell, R. G. G. (2007) · PEDIATRICS · doi:10.1542/peds.2006-2023h · Cited by 513
Self-citation
The Pathogenesis of Bisphosphonate-Related Osteonecrosis of the Jaw: So Many Hypotheses, So Few Data
Allen, M. R., & Burr, D. B. (2009) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2009.01.007 · Cited by 449
Bisphosphonates
Russell, R. G. G. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1346.041 · Cited by 416
Self-citation
The relationship between the chemistry and biological activity of the bisphosphonates
Ebetino, F. H., Hogan, A. L., Sun, S., Tsoumpra, M. K., Duan, X., Triffitt, J. T., Kwaasi, A. A. A., Dunford, J. E., Barnett, B. L., Oppermann, U. C. T., et al. (2011) · Bone · doi:10.1016/j.bone.2011.03.774 · Cited by 402
Self-citation
Bisphosphonates
Russell, R. G. G., Xia, Z., Dunford, J. E., Oppermann, U. C. T., Kwaasi, A. A. A., Hulley, P. A., Kavanagh, K. L., Triffitt, J. T., Lundy, M. W., Phipps, R. J., et al. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1402.089 · Cited by 407
Self-citation
Adverse Effects of Bisphosphonates
Adami, S., & Zamberlan, N. (1996) · Drug Safety · doi:10.2165/00002018-199614030-00003 · Cited by 371
Biomimetic Hydroxyapatite–Drug Nanocrystals as Potential Bone Substitutes with Antitumor Drug Delivery Properties
Palazzo, B., Iafisco, M., Laforgia, M., Margiotta, N., Natile, G., Bianchi, C. L., Walsh, D., Mann, S., & Roveri, N. (2007) · Advanced Functional Materials · doi:10.1002/adfm.200600361 · Cited by 344
pH-Activated Nanoparticles for Controlled Topical Delivery of Farnesol To Disrupt Oral Biofilm Virulence
Horev, B., Klein, M. I., Hwang, G., Li, Y., Kim, D., Koo, H., & Benoit, D. S. W. (2015) · ACS Nano · doi:10.1021/nn507170s · Cited by 342
Progress on the preparation of nanocrystalline apatites and surface characterization: Overview of fundamental and applied aspects
Gómez‐Morales, J., Iafisco, M., Delgado‐López, J. M., Sarda, S., & Drouet, C. (2012) · Progress in Crystal Growth and Characterization of Materials · doi:10.1016/j.pcrysgrow.2012.11.001 · Cited by 271
Recent advances in understanding the mechanism of action of bisphosphonates
Coxon, F. P., Thompson, K., & Rogers, M. J. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.03.005 · Cited by 254
Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate
Allen, M. R., Iwata, K., Phipps, R. J., & Burr, D. B. (2006) · Bone · doi:10.1016/j.bone.2006.04.028 · Cited by 259
Self-citation
Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells
Coxon, F. P., Thompson, K., Roelofs, A. J., Ebetino, F. H., & Rogers, M. J. (2008) · Bone · doi:10.1016/j.bone.2007.12.225 · Cited by 248
Self-citation
Simulations of inorganic–bioorganic interfaces to discover new materials: insights, comparisons to experiment, challenges, and opportunities
Heinz, H., & Ramezani‐Dakhel, H. (2016) · Chemical Society Reviews · doi:10.1039/c5cs00890e · Cited by 239
‘Magic bullets’ for bone diseases: progress in rational design of bone-seeking medicinal agents
Zhang, S., Gangal, G., & Uludağ, H. (2006) · Chemical Society Reviews · doi:10.1039/b512310k · Cited by 237
Pharmacology of bisphosphonates
Cremers, S., Drake, M. T., Ebetino, F. H., Bilezikian, J. P., & Russell, R. G. G. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13867 · Cited by 246
Self-citation
Early Responsiveness of Women with Osteoporosis to Teriparatide After Therapy with Alendronate or Risedronate
Miller, P. D., Delmas, P. D., Lindsay, R., Watts, N. B., Luckey, M. M., Adachi, J. D., Saag, K. G., Greenspan, S. L., Seeman, E., Boonen, S., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0353 · Cited by 222
Bisphosphonate effects on bone turnover, microdamage, and mechanical properties: What we think we know and what we know that we don't know
Allen, M. R., & Burr, D. B. (2011) · Bone · doi:10.1016/j.bone.2010.10.159 · Cited by 219
Pharmacology of bisphosphonates
Cremers, S., & Papapoulos, S. E. (2011) · Bone · doi:10.1016/j.bone.2011.01.014 · Cited by 223
Infrared Assessment of Bone Quality: A Review
Paschalis, E. P., Mendelsohn, R., & Boskey, A. L. (2011) · Clinical Orthopaedics and Related Research · doi:10.1007/s11999-010-1751-4 · Cited by 225
Polycaprolactone-Coated 3D Printed Tricalcium Phosphate Scaffolds for Bone Tissue Engineering: In Vitro Alendronate Release Behavior and Local Delivery Effect on In Vivo Osteogenesis
Tarafder, S., & Bose, S. (2014) · ACS Applied Materials & Interfaces · doi:10.1021/am501048n · Cited by 205
99mTc-Bisphosphonate-Iron Oxide Nanoparticle Conjugates for Dual-Modality Biomedical Imaging
de Rosales, R. T. M., Tavaré, R., Glaria, A., Varma, G., Protti, A., & Blower, P. J. (2011) · Bioconjugate Chemistry · doi:10.1021/bc100483k · Cited by 208
Aminobisphosphonates Cause Osteoblast Apoptosis and Inhibit Bone Nodule Formation In Vitro
Idris, A. I., Rojas, J., Greig, I. R., Hof, R. V., & Ralston, S. H. (2008) · Calcified Tissue International · doi:10.1007/s00223-008-9104-y · Cited by 206
Targeted delivery to bone and mineral deposits using bisphosphonate ligands
Cole, L. E., Vargo-Gogola, T. C., & Roeder, R. K. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.005 · Cited by 197
Paget's Disease of Bone: An Endocrine Society Clinical Practice Guideline
Singer, F. R., Bone, H. G., Hosking, D. J., Lyles, K. W., Murad, M. H., Reid, I. R., & Siris, E. S. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2910 · Cited by 194
Accurate Force Field Parameters and pH Resolved Surface Models for Hydroxyapatite to Understand Structure, Mechanics, Hydration, and Biological Interfaces
Lin, T.-J., & Heinz, H. (2016) · The Journal of Physical Chemistry C · doi:10.1021/acs.jpcc.5b12504 · Cited by 188
Biomedical applications of bisphosphonates
Giger, E. V., Castagner, B., & Leroux, J. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.01.032 · Cited by 192
Drug delivery from ordered mesoporous matrices
Manzano, M., Colilla, M., & Vallet‐Regí, M. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240903304024 · Cited by 186
Alendronate coated poly-lactic-co-glycolic acid (PLGA) nanoparticles for active targeting of metastatic breast cancer
Thamake, S. I., Raut, S., Gryczynski, Z. K., Ranjan, A. P., & Vishwanatha, J. K. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.06.026 · Cited by 185
Targeting nanoparticles for diagnosis and therapy of bone tumors: Opportunities and challenges
Gao, X., Li, L., Cai, X., Huang, Q., Xiao, J., & Cheng, Y. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120404 · Cited by 182
Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: The risedronate and alendronate (REAL) cohort study
Silverman, S. L., Watts, N. B., Delmas, P. D., Lange, J. L., & Lindsay, R. (2006) · Osteoporosis International · doi:10.1007/s00198-006-0274-z · Cited by 176
Targeting strategies for bone diseases: signaling pathways and clinical studies
Xu, H., Wang, W., Liu, X., Huang, W. H., Chen, Z., Xu, Y., Yang, H., Bai, J., & Geng, D. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01467-8 · Cited by 177
Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo
Roelofs, A. J., Coxon, F. P., Ebetino, F. H., Lundy, M. W., Henneman, Z. J., Nancollas, G. H., Sun, S., Błażewska, K. M., Bala, J. L. F., Kashemirov, B. A., et al. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.091009 · Cited by 168
Self-citation
Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone
Hortobágyi, G. N., Poznak, C. H. V., Harker, W. G., Gradishar, W. J., Chew, H. K., Dakhil, S. R., Haley, B., Sauter, N. P., Mohanlal, R. W., Zheng, M., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.6316 · Cited by 163
Long-Term Control of Bone Turnover in Paget's Disease With Zoledronic Acid and Risedronate
Hosking, D. J., Lyles, K. W., Brown, J. P., Fraser, W. D., Miller, P. D., Díaz Curiel, M., Devogelaer, J., Hooper, M. J., Su, G., Zelenakas, K., et al. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.061001 · Cited by 161
Adverse Effects of Bisphosphonates
Abrahamsen, B. (2010) · Calcified Tissue International · doi:10.1007/s00223-010-9364-1 · Cited by 163
Effect of Long‐Term Oral Bisphosphonates on Implant Wound Healing: Literature Review and a Case Report
Wang, H., Weber, D., & McCauley, L. K. (2007) · Journal of Periodontology · doi:10.1902/jop.2007.060239 · Cited by 158
Bisphosphonate-Related Osteonecrosis of the Jaw: Is pH the Missing Part in the Pathogenesis Puzzle?
Otto, S., Hafner, S., Mast, G., Tischer, T., Volkmer, E., Schieker, M., Stürzenbaum, S. R., von Tresckow, E., Kolk, A., Ehrenfeld, M., et al. (2010) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2009.07.079 · Cited by 167
Alendronate–hydroxyapatite nanocomposites and their interaction with osteoclasts and osteoblast-like cells
Boanini, E., Torricelli, P., Gazzano, M., Giardino, R., & Bigi, A. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2007.10.040 · Cited by 155
Design of calcium phosphate ceramics for drug delivery applications in bone diseases: A review of the parameters affecting the loading and release of the therapeutic substance
Parent, M., Baradari, H., Champion, É., Damia, C., & Viana, M. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.02.012 · Cited by 153
Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial
Brown, J. P., Roux, C., Törring, O., Ho, P., Jensen, J. B., Gilchrist, N. L., Recknor, C. P., Austin, M., Wang, A., Grauer, A., et al. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1808 · Cited by 149
The effect of surface immobilized bisphosphonates on the fixation of hydroxyapatite-coated titanium implants in ovariectomized rats
Gao, Y., Zou, S., Liu, X., Bao, C., & Hu, J. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2008.12.025 · Cited by 143
Implant Placement in Patients with Oral Bisphosphonate Therapy: A Case Series
Shabestari, G. O., Shayesteh, Y. S., Khojasteh, A., Alikhasi, M., Moslemi, N., Аминиан, А., Masaeli, R., Eslami, B., & Treister, N. S. (2009) · Clinical Implant Dentistry and Related Research · doi:10.1111/j.1708-8208.2009.00150.x · Cited by 143
A review of chemical surface modification of bioceramics: Effects on protein adsorption and cellular response
Lee, W., Loo, C., & Rohanizadeh, R. (2014) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2014.07.029 · Cited by 141
Osteonecrosis of the Jaw: Effect of Bisphosphonate Type, Local Concentration, and Acidic Milieu on the Pathomechanism
Otto, S., Pautke, C., Opelz, C., Westphal, I., Drosse, I., Schwager, J., Bauss, F., Ehrenfeld, M., & Schieker, M. (2010) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2010.07.017 · Cited by 145
Synthetic hydroxyapatite in pharmaceutical applications
Kolmas, J., Krukowski, S., Laskus, A., & Jurkitewicz, M. (2015) · Ceramics International · doi:10.1016/j.ceramint.2015.10.048 · Cited by 140
Functionalization degree of SBA-15 as key factor to modulate sodium alendronate dosage
Nieto, A., Balas, F., Colilla, M., Manzano, M., & Vallet‐Regí, M. (2008) · Microporous and Mesoporous Materials · doi:10.1016/j.micromeso.2008.03.025 · Cited by 137
Specificity of Growth Inhibitors and their Cooperative Effects in Calcium Oxalate Monohydrate Crystallization
Farmanesh, S., Ramamoorthy, S., Chung, J., Asplin, J. R., Karande, P., & Rimer, J. D. (2013) · Journal of the American Chemical Society · doi:10.1021/ja410623q · Cited by 136
Inhibition of osteoblast function in vitro by aminobisphosphonates
Orriss, I. R., Key, M. L., Colston, K. W., & Arnett, T. R. (2008) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21983 · Cited by 134
Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday
Curtis, J. R., Westfall, A. O., Cheng, H. T., Delzell, E., & Saag, K. G. (2008) · Osteoporosis International · doi:10.1007/s00198-008-0604-4 · Cited by 134
Bisphosphonates for postmenopausal osteoporosis
Eastell, R., Walsh, J., Watts, N. B., & Siris, E. S. (2011) · Bone · doi:10.1016/j.bone.2011.02.011 · Cited by 131
The use of bisphosphonates in women prior to or during pregnancy and lactation
Ioannis, S. P., Liakou, C. G., Katsalira, A., Trovas, G., Lyritis, G. P., Παπαϊωάννου, Ν., & Tournis, S. (2011) · HORMONES · doi:10.14310/horm.2002.1319 · Cited by 133
A single infusion of zoledronic acid produces sustained remissions in paget disease: Data to 6.5 years
Reid, I. R., Lyles, K. W., Su, G., Brown, J. P., Walsh, J. P., del Pino‐Montes, J., Miller, P. D., Fraser, W. D., Cafoncelli, S., Bucci-Rechtweg, C. M., et al. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.438 · Cited by 130
Current Understanding of the Pathophysiology of Osteonecrosis of the Jaw
Chang, J., Hakam, A. E., & McCauley, L. K. (2018) · Current Osteoporosis Reports · doi:10.1007/s11914-018-0474-4 · Cited by 134
Bone targeted nano-drug and nano-delivery
Wu, Y., Sun, B. F., Tang, Y. K., Shen, A., Lin, Y., Zhao, X., Li, J., Monteiro, M. J., & Gu, W. (2024) · Bone Research · doi:10.1038/s41413-024-00356-2 · Cited by 127
Biomaterial-assisted local and systemic delivery of bioactive agents for bone repair
Zeng, Y., Hoque, J., & Varghese, S. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.01.060 · Cited by 128
A new alendronate doped HAP nanomaterial for Pb2+, Cu2+ and Cd2+ effect absorption
Ma, J., Xia, M., Zhu, S., & Wang, F. (2020) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2020.123143 · Cited by 124
Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women
Boonen, S., Sellmeyer, D. E., Lippuner, K., Orlov-Morozov, A., Abrams, K. B., Mesenbrink, P. G., Eriksen, E. F., & Miller, P. D. (2008) · Kidney International · doi:10.1038/ki.2008.193 · Cited by 122
Bisphosphonates: how do they work?
Papapoulos, S. E. (2008) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.07.001 · Cited by 133
Bone mineralization: from tissue to crystal in normal and pathological contexts
Bala, Y., Farlay, D., & Boivin, G. (2012) · Osteoporosis International · doi:10.1007/s00198-012-2228-y · Cited by 133
Bone Turnover in Bone Biopsies of Patients with Low-Energy Cortical Fractures Receiving Bisphosphonates: A Case Series
Armamento‐Villareal, R., Napoli, N., Diemer, K., Watkins, M. P., Civitelli, R., Teitelbaum, S. L., & Novack, D. V. (2009) · Calcified Tissue International · doi:10.1007/s00223-009-9263-5 · Cited by 122
A collagen–hydroxyapatite scaffold allows for binding and co-delivery of recombinant bone morphogenetic proteins and bisphosphonates
Murphy, C. M., Schindeler, A., Gleeson, J. P., Yu, N. Y. C., Cantrill, L. C., Mikulec, K., Peacock, L., O’Brien, F. J., & Little, D. G. (2014) · Acta Biomaterialia · doi:10.1016/j.actbio.2014.01.016 · Cited by 119
Bone Material Properties in Trabecular Bone From Human Iliac Crest Biopsies After 3- and 5-Year Treatment With Risedronate
Durchschlag, E., Paschalis, E. P., Zoehrer, R., Roschger, P., Fratzl, P., Recker, R. R., Phipps, R. J., & Klaushofer, K. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060701 · Cited by 122
Self-citation
A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density
Saag, K. G., Lindsay, R., Kriegman, A. G., Beamer, E., & Zhou, W. (2007) · Bone · doi:10.1016/j.bone.2007.01.016 · Cited by 118
Differences between bisphosphonates in binding affinities for hydroxyapatite
Lawson, M. A., Xia, Z., Barnett, B. L., Triffitt, J. T., Phipps, R. J., Dunford, J. E., Locklin, R. M., Ebetino, F. H., & Russell, R. G. G. (2009) · Journal of Biomedical Materials Research Part B Applied Biomaterials · doi:10.1002/jbm.b.31500 · Cited by 117
Self-citation
Postmenopausal osteoporosis treatment with antiresorptives: Effects of discontinuation or long-term continuation on bone turnover and fracture risk—a perspective
Boonen, S., Ferrari, S., Miller, P. D., Eriksen, E. F., Sambrook, P. N., Compston, J. E., Reid, I. R., Vanderschueren, D., & Cosman, F. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1570 · Cited by 114
Bisphosphonate treatment modifies canine bone mineral and matrix properties and their heterogeneity
Gourion‐Arsiquaud, S., Allen, M. R., Burr, D. B., Vashishth, D., Tang, S. Y., & Boskey, A. L. (2009) · Bone · doi:10.1016/j.bone.2009.11.011 · Cited by 118
Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up)
Leder, B. Z., Tsai, J. N., Jiang, L. A., & Lee, H. (2017) · Bone · doi:10.1016/j.bone.2017.03.006 · Cited by 112
Drug delivery systems functionalized with bone mineral seeking agents for bone targeted therapeutics
Rotman, S. G., Grijpma, D. W., Richards, R. G., Moriarty, T. F., Eglin, D., & Guillaume, O. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.11.009 · Cited by 109
Bone micromechanical properties are compromised during long-term alendronate therapy independently of mineralization
Bala, Y., Dépalle, B., Farlay, D., Douillard, T., Meille, S., Follet, H., Chapurlat, R. D., Chevalier, J., & Boivin, G. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1501 · Cited by 114
Influence of bone affinity on the skeletal distribution of fluorescently labeled bisphosphonates in vivo
Roelofs, A. J., Stewart, C. A., Sun, S., Błażewska, K. M., Kashemirov, B. A., McKenna, C. E., Russell, R. G. G., Rogers, M. J., Lundy, M. W., Ebetino, F. H., et al. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1543 · Cited by 111
Self-citation
Bisphosphonates for the treatment of osteoporosis: insights for clinicians
Lewiecki, E. M. (2010) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622310374783 · Cited by 112
The role of SBA-15 in drug delivery
Vavsari, V. F., Ziarani, G. M., & Badiei, A. (2015) · RSC Advances · doi:10.1039/c5ra17780d · Cited by 108
Composite Nanocrystals Provide New Insight on Alendronate Interaction with Hydroxyapatite Structure
Boanini, E., Gazzano, M., Rubini, K., & Bigi, A. (2007) · Advanced Materials · doi:10.1002/adma.200602497 · Cited by 106
Parathyroid Hormone and Parathyroid Hormone-Related Protein Analogs in Osteoporosis Therapy
Leder, B. Z. (2017) · Current Osteoporosis Reports · doi:10.1007/s11914-017-0353-4 · Cited by 105
Reduction in the Risk of Clinical Fractures After a Single Dose of Zoledronic Acid 5 Milligrams
Reid, I. R., Black, D. M., Eastell, R., Bucci-Rechtweg, C. M., Su, G., Hue, T. F., Mesenbrink, P. G., Lyles, K. W., & Boonen, S. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2868 · Cited by 104
pH-responsive NIR enhanced drug release from gold nanocages possesses high potency against cancer cells
Shi, P., Qu, K., Wang, J., Li, M. C., Ren, J., & Qu, X. (2012) · Chemical Communications · doi:10.1039/c2cc33543c · Cited by 103
Mandibular necrosis in beagle dogs treated with bisphosphonates
Burr, D. B., & Allen, M. R. (2009) · Orthodontics and Craniofacial Research · doi:10.1111/j.1601-6343.2009.01456.x · Cited by 103
Consensus on the utility of bone markers in the malignant bone disease setting
Coleman, R. E., Costa, L., Fred Saad, C., Cook, R. J., Hadji, P., Terpos, E., Garnero, P., Brown, J. E., Body, J., Smith, M. R., et al. (2011) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.02.005 · Cited by 103
Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis
Russell, R. G. G. (2010) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s8054 · Cited by 102
Self-citation
The Nature and Frequency of Bisphosphonate-Associated Osteonecrosis of the Jaws in Dental Implant Patients: A South Australian Case Series
Goss, A. N., Bartold, P. M., Sambrook, P. J., & Hawker, P. (2010) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2009.09.037 · Cited by 100
Surface Electrochemistry of Mesoporous Silicas as a Key Factor in the Design of Tailored Delivery Devices
Nieto, A., Colilla, M., Balas, F., & Vallet‐Regí, M. (2010) · Langmuir · doi:10.1021/la904820k · Cited by 99
Safety of Bisphosphonates in the Treatment of Osteoporosis
Recker, R. R., Lewiecki, E. M., Miller, P. D., & Reiffel, J. A. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.12.004 · Cited by 98
Infrared, Raman and NMR investigations of risedronate adsorption on nanocrystalline apatites
Errassifi, F., Sarda, S., Barroug, A., Legrouri, A., Sfihi, H., & Rey, C. C. (2014) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2014.01.017 · Cited by 99
Zoledronic Acid (Reclast®, Aclasta®): A Review in Osteoporosis
Dhillon, S. (2016) · Drugs · doi:10.1007/s40265-016-0662-4 · Cited by 96
Bisphosphonate Associated Osteonecrosis of the Jaw: An Update on Pathophysiology, Risk Factors, and Treatment
Rasmusson, L., & Abtahi, J. (2014) · International Journal of Dentistry · doi:10.1155/2014/471035 · Cited by 104
Molecular mechanisms of crystallization impacting calcium phosphate cements
Giocondi, J. L., El-Dasher, B. S., Nancollas, G. H., & Orme, C. A. (2010) · Philosophical Transactions of the Royal Society A Mathematical Physical and Engineering Sciences · doi:10.1098/rsta.2010.0006 · Cited by 95
Self-citation
Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly Zoledronic acid
Gamsjaeger, S., Buchinger, B., Zwettler, E., Recker, R. R., Black, D. M., Gasser, J. A., Eriksen, E. F., Klaus Klaushofer, A., & Paschalis, E. P. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.180 · Cited by 94

Authors: Nancollas, G. H., Tang, R., Phipps, R. J., Henneman, Z., Gulde, S., Wu, W., Mangood, A., Russell, R. G. G., & Ebetino, F. H.
Affiliations: University at Buffalo, State University of New York (US)
Procter & Gamble (United States) (US)
Nuffield Orthopaedic Centre (GB)
Corresponding author: Ebetino, F.H.
ORCID: Tang, R.
Mangood, A.
Russell, R.G.G.
Ebetino, F.H.
Venue: Bone
Publisher: Elsevier BV
Published: 2006-05
Volume: 38
Issue: 5
Pages: 617-627
ISSN: 1873-2763 (ISSN-L)
8756-3282
DOI: 10.1016/j.bone.2005.05.003
OpenAlex: W2128778774
Cited by: 862
References: 75
Citations by year: 2026: 17 · 2025: 23 · 2024: 15 · 2023: 24 · 2022: 41 · 2021: 29 · 2020: 45 · 2019: 39 · 2018: 44 · 2017: 40 · 2016: 39 · 2015: 45 · 2014: 55 · 2013: 48 · 2012: 44
FWCI: 18.97
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Bone (publishedVersion)
PubMed (publishedVersion)
Funders: National Institute of Dental and Craniofacial Research (DE03223)
National Institutes of Health
Topics: Health Sciences › Medicine › Oncology › Bone health and treatments
Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
Keywords: bisphosphonates, hydroxyapatite, drug adsorption, binding affinity, crystal growth inhibition, zeta potential, interfacial tension, zoledronic acid, alendronate, ibandronate, risedronate, etidronate, clodronate, bone mineral, osteoporosis, duration of action, protein prenylation
MeSH terms: Bone and Bones, Crystallization, Diphosphonates, Humans, Stress, Mechanical, Durapatite, Bone Density Conservation Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks